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OBJECTIVE: The evaluation of S100B protein expression in the human heart and its correlation with drug-related
death.
METHOD: Left ventricular samples were collected from 74 serial forensic autopsies (15 overdose-related deaths; 59
non-overdose-related deaths) from 2007 to 2010. Tissue sections from each sample were immunostained for S100B
protein by a commercial antibody.
RESULTS: The S100B protein was detected in the heart samples of all 15 cases of drug-related deaths; S100B
immunoreactivity was mainly observed in the cytoplasm of cardiomyocytes and as globular deposits in the
interstitial spaces. No reactivity or weak reactivity was found in the cardiomyocytes of the 59 subjects who died of
other causes.
CONCLUSION: Our preliminary data show that the S100B protein accumulates in injured cardiomyocytes during
drug-related sudden death. Given the near absence of S100B protein in the heart of subjects who died from causes
other than drug overdose, S100B immunopositivity may be used as a new ancillary screening tool for the
postmortem diagnosis of overdose-related cardiac death.
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INTRODUCTION
Cocaine, a crystalline tropane alkaloid obtained from the
leaves of the coca plant, is one of the most commonly used
illicit drugs and acts as a powerful sympathomimetic agent,
with local and systemic effects. Local effects are the
consequence of the inhibition of membrane permeability
to sodium during depolarization and the inhibition of the
transmission of electrical impulses. Systemic effects are
attributed to the inhibition of presynaptic reuptake of
norepinephrine and dopamine and the secondary excess
production of these neurotransmitters at receptor sites on
the postganglionic neuron (1).
The effects of cocaine on the cardiovascular system have
been extensively documented in both animal models and
humans. Cocaine administered to rats produces atrial
and ventricular arrhythmias and myocardial ischemia
with coronary vasoconstriction (2). High-grade ventricular
arrhythmias, myocardial infarction, and sudden cocaine-
related death have been reported in humans (3). In the same
study, cocaine use was shown to precipitate a cardiac
event with myocardial infarct even after recreational use.
Additionally, clinical evidence has shown that adverse cardiac
effects are frequent during medicinal cocaine use, in which the
drug is applied intranasally and intratracheally as a local
anesthetic (4-6). Cocaine use has also been associated with
other cardiac disorders, such as systemic hypertension, aortic
aneurysms, torsades de pointes, arrhythmia, sudden coronary
death (7), ischemia, ventricular tachycardia, and ventricular
fibrillation (8-12). Cocaine may change cardiac rhythm by
inhibiting sodium transport across membranes during depo-
larization and thus inhibiting the generation and conduction of
action potentials (13,14). Cocaine-related myocardial ischemia
or infarction may occur immediately after cocaine use: cocaine
increases the risk of acute myocardial infarct (AMI) by up to
24-fold in the first hours after use (15). The incidence of AMI is
much higher in younger patients (aged 18-45 years) (16),
particularly in those with other cardiac risk factors (17).
The principal mechanism of cocaine-related heart damage
appears to be myocardial ischemia. Three pharmacological
mechanisms, likely acting in combination, are involved in
the pathogenesis of cocaine-related ischemia: first, cocaine
produces an increase in heart rate and blood pressure as a
consequence of adrenergic stimulation; second, it causes
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coronary vasoconstriction due to the stimulation of coronary
a-adrenergic receptors; and third, it leads to an increase in
platelet aggregability. Furthermore, the mismatch between
myocardial oxygen supply and the demand from cocaine-
induced vasoconstriction and increased myocardial work-
load are often invoked as the major mechanisms by which
cocaine might induce myocardial ischemia.
In contrast, there is limited information available on the
acute effects of heroin on the heart; to the best of our
knowledge, only a few cases of AMI after heroin injections
have been reported (18). Experimental studies have demon-
strated that heroin may cause systemic and direct effects on
the heart (19,20), most likely mediated by a local coronary
spasm or inflammation (21). Heroin could act directly on the
vasomotor center by increasing parasympathetic activity,
producing bradycardia and hypotension and stimulating
the release of histamine from mast cells (22,23). Heroin-
induced coronary vasospasm after heroin sniffing has also
been reported (24-26). Taken together, these reports indicate
that heroin may have a direct toxic effect on coronary
arteries and induce acute coronary occlusion.
The S100 protein family comprises 16 low-molecular-
weight (21 KDa) calcium-binding proteins that contain two
calcium-binding sites. S100B, one of the two founding
members of this family, is concentrated in oligodendrocytes,
astrocytes, ependymocytes, Schwann cells and neurons (27).
In clinical practice, it is a reliable biochemical marker of
cerebral damage and is also utilized in postmortem diagnosis
in medico-legal autopsy cases (28). Because S100B protein
plasma levels have been shown to increase during ischemic
stroke, S100 protein serum levels are used in clinical practice
to monitor neurovascular status and functional outcome in
subjects affected by cerebral damage (29) or subarachnoid
hemorrhage (30,31). Elevated serum S100B levels have been
reported in patients affected by obstructive sleep apnea
syndrome (32). Moreover, S100B urine levels have been
proposed as a useful tool to identify newborns that are at a
higher risk of neonatal death (33) or full-term infants at risk of
hypoxic-ischemic encephalopathy (34).
S100B is not restricted to the nervous system; chondro-
cytes, adipocytes, melanocytes, and Langerhans cells may
also release S100B (35,36). In addition, recent investigations
showed that elevated S100B serum levels may also be
detected in patients without head injury, suggesting that it
may originate from other damaged tissues (37,38), such as
skeletal myofibers, muscle satellite cells and myoblasts.
Isolated rat heart cells were shown to release S100B (39),
and the myocardium was indicated as the putative main
source for the increase in S100B serum levels in patients
affected by dilated cardiomyopathy (40). Recently, S100B
protein expression was shown to be induced in the heart of
human subjects after myocardial infarction (41), and it has
been proposed as a marker of poor prognosis in patients
undergoing cardiac surgery (42).
Based on these data, the current study was aimed at
verifying, with immunohistochemical data, whether the
S100B protein is expressed in the hearts of subjects who
underwent sudden cardiac death, including drug addicts
and patients without a history of drug abuse.
MATERIALS AND METHODS
Seventy-four serial autopsies conducted from 2007 to 2010
(40 males and 34 females) were included in the present
study. The subjects tested were subdivided into two main
groups: the overdose group (15 subjects; cocaine, heroin or
polypharmacological admixtures, including ecstasy) and the
non-overdose group (59 subjects; traumatic and non-trau-
matic deaths). The traumatic group was subdivided into
three subgroups (sidearms, firearms, and drowning). The
victims ranged in age from 9 to 85 years old. In each case, a
full autopsy and toxicological analysis were performed
within 24-72 hours after death. No macroscopic sign of
congenital cardiomyopathy was found in any case. The
macroscopic examination of the heart did not show any sign
of severe coronary atherosclerosis. Multiple tissue samples
collected from the left ventricular wall were fixed in 10%
formalin, routinely processed and paraffin-embedded. The
initial block was cut into 6-7 blocks approximately 2-3 mm
wide. At least two histological sections were prepared from
each block. The tissue sections were stained with hematox-
ylin-eosin or immunostained with a polyclonal rabbit anti-
S100B antibody (DakoCytomation A/S, Glostrup, diluted 1/
2000) followed by incubation for three hours at 37 C˚ in with
universal streptavidin/biotin immunoperoxidase detection
reagents. Endogenous peroxidase was inactivated by incu-
bation with 3% hydrogen peroxide for 5 min. To confirm the
specificity of immunostaining, phosphate-buffered saline
was substituted for the primary antibody in control sections.
The peripheral nerves present in each section served as a
positive internal control. Stained sections were read by two
pathologists blinded to the clinical diagnosis.
RESULTS
Immunoreactivity for the S100B protein was mainly
detected in the overdose group; less reactivity was detected
in the 59 subjects in the non-overdose-related group (Figure 1).
The pattern of S100B reactivity varied between cases, with
different localization and different intensities. S100B staining
was mainly observed inside the cytoplasm of scattered
cardiac cells (Figure 2). The signals appeared as differently
sized globular deposits and granules, often located near the
nucleus. Similar globular deposits were also found in the
interstitial spaces and were unevenly distributed throughout
the cardiac tissue (Figure 3). Immunoreactive signals were
also occasionally found in the perivascular spaces in the
cytoplasm of stromal cells surrounding the wall of intra-
cardiac arteries. No significant differences were found among
the different subgroups in which the overdose patients were
subdivided: S100B protein deposits were found in the heart in
cocaine-, heroin- and other drug-related deaths. We observed
the highest levels of immunoreactivity for S100B in 3 patients
with a clinical history of combined cocaine and heroin abuse
(Figure 4). In these cases, a large number of cardiomyocytes
showed very large globular deposits of the protein.
No reactivity for the S100B protein was detected in the
subpericardial fatty tissue or other soft tissues, with the
exclusion of nerve fibers, which represented the internal
positive control.
Finally, hematoxylin-eosin staining was performed to
investigate the pathological status of these hearts; edema,
and a wavy arrangement of cardiomyocytes were observed
in all S100B-positive cases (Figure 5).
DISCUSSION
The current study investigated whether the S100B protein
is expressed and immunodetectable in the hearts of patients
Cardiac changes following overdose
Faa A et al.
CLINICS 2012;67(7):821-826
822
who died due to drug overdose and whether different drugs
(heroin, cocaine, and polypharmacological admixtures,
including ecstasy) could affect S100B protein retention in
cardiomyocytes.
Our preliminary data clearly show that the S100B protein
is significantly more expressed in the hearts of drug users,
regardless of the type of drug employed, compared with
patients who died from traumatic or other pathological
events. From a practical point of view, this finding suggests
that S100B immunostaining could be performed in all cases
of cardiac death possibly related to drug abuse to confirm
the role of drug use as a cause of death.
The presence of the S100B protein inside the cytoplasm of
cardiomyocytes and in the interstitial spaces around cardiac
cells, and the presence of myocytolysis clearly suggest
cardiomyocytes as the putative main source of S100B
production and release. The absence of immunoreactivity
for the protein in the subepicardial fat tissue in this study
is inconsistent with the previous hypothesis that cardiac
adipocytes are the main source of S100B protein in the heart.
Our histological data confirm the typical histological
findings previously reported in cocaine-related death; i.e.,
contraction band necrosis (CBN), also referred to as
coagulative myocytolysis, and an anomalous hypereosino-
philic crossband formed by segments of hypercontracted
sarcomeres with extremely thickened Z lines (43).
Another interesting finding in our study is that a similar
S100B protein expression pattern is observed in both cocaine
and heroin abusers. One possible explanation for this finding
could be the acute stress caused by both drugs on the central
nervous system, followed by the induction of S100B protein
overproduction in cardiomyocytes (44).
Particularly strong reactivity for S100B protein was
observed in some cases in which toxicological analyses
suggested concomitant cocaine and heroin abuse. This finding
supports the assumption that both drugs may act on the same
pathways, cooperating in S100B protein overproduction,
storage and release. Because both of these substances are
metabolized by the same enzymes, human carboxylesterases
(hCEs), we might postulate that heroin and cocaine could
interfere with each other at a metabolic level when taken
together, giving rise to the overproduction of S100B and
leading to significant cardiac storage of the protein (45).
However, to the best of our knowledge, the exact mechanism
by which S100B protein is overexpressed at the cardiac level
in overdose-related deaths remains unclear. The over-expres-
sion of S100B protein might depend on environmental factors;
it has been shown that several substances, including
norepinephrine, phenylephrine, interleukin 1b (IL-1b), b-
amyloid, antidepressants and pro-inflammatory cytokines,
may up- or down-regulate S100B expression. Moreover,
S100B expression has been attributed to catecholamines in
cardiomyocytes surviving infarction (46). In fact, the S100B
protein, which is undetectable in normal cardiomyocytes, is
induced in the ischemic or post-infarctionmyocardium. These
observations suggest that S100B gene expression is under
complex transcriptional regulation. S100B gene expression
appears to be constitutively repressed in all cell types,
implying that the expression of S100B in a given cell type
Figure 1 - S100B positivity and cause of death.
Figure 2 - Diffuse S100B intermyocite positivity with some
positivity in perivessels spaces (arrow).
Figure 3 - S100B positivity in inter-myocytes spaces with
accentuation of Schwann cells in a nerve twig X 400.
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requires induction of an appropriate factor to counter the
action of some negative regulatory elements (47).
In this study, the S100B protein was also detectable in
extracellular spaces, in which it might exert multiple
important effects. Previous research has shown that astro-
cytes may be stimulated to excrete S100B by relatively high
levels of cytosolic Ca (48). A similar enhancing action of
calcium ions could also be hypothesized in cardiomyocytes
under hypoxic stress. A secondary hypothesis to explain the
presence of S100B outside of cells is leakage from damaged
cells (49). Our observation of coagulative myocytolysis in all
cases of drug abuse might confirm this hypothesis.
Whatever the source of extracellular S100B and the
mechanism underlying its release, extracellular S100B
might attain local concentrations sufficient to affect cellular
activities by paracrine, autocrine and endocrine manners.
The extracellular effects of S100B protein on cardiomyo-
cytes and inflammatory cells could be mediated by the
receptor for advanced glycation end-products (RAGE), a
member of the immunoglobulin superfamily that is gen-
erally considered a central mediator of ischemia/reperfu-
sion injury in the heart (50-53).
Dissecting the complex pattern of intracellular signaling
resulting from hypoxic insults to ischemia and reperfusion
(I/R) may be a considerable challenge.
In the complex environmental interactions in the injured
heart, several ‘danger signals’ are commonly liberated from
ischemic cells (52). These signals signal the ischemic insult
to other cells and mediate an inflammatory response but
also promote tissue growth and remodeling that is partially
mediated via RAGE activation. The S100B protein could
participate in this process.
Our data confirm the hypothesized existence of a
common pathway through which multiple drugs (heroin
and cocaine) might cause S100B protein cardiac overload
and release. The reported increase in S100B urine levels in
newborns at higher risk of neonatal death (33) due to
hypoxic-ischemic encephalopathy or asphyxia (34) suggest
that severe hypoxia is the common mechanism of drug-
induced S100B protein accumulation at the cardiac level.
Finally, our results, though limited by the small number of
cases available and the numerous uncontrolled variables
involved (e.g., doses, survival time, individual tolerance,
post-mortem redistribution, drug stability, etc.), support the
hypothesis that the immunohistochemical detection of sig-
nificant S100B protein in the heart supports a suspicion of drug
addiction and could distinguish overdose-related death from
traumatic or ischemia-related death. Based on our preliminary
data, we suggest that the immunodetection of S100B protein in
the heart could be useful to not only help determine the cause
of death in complicated or atypical cases but also provide
evidence in individual cases to be shown in court.
Further studies are needed to clarify the metabolic link
between overdose and S100B protein overload in the heart
of drug abuse-related sudden deaths.
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